Passa al contenuto
Merck

Oncogenic extracellular HSP70 disrupts the gap-junctional coupling between capillary cells.

Oncotarget (2015-04-15)
Dominique Thuringer, Kevin Berthenet, Laurent Cronier, Gaetan Jego, Eric Solary, Carmen Garrido
ABSTRACT

High levels of circulating heat shock protein 70 (HSP70) are detected in many cancers. In order to explore the effects of extracellular HSP70 on human microvascular endothelial cells (HMEC), we initially used gap-FRAP technique. Extracellular human HSP70 (rhHSP70), but not rhHSP27, blocks the gap-junction intercellular communication (GJIC) between HMEC, disrupts the structural integrity of HMEC junction plaques, and decreases connexin43 (Cx43) expression, which correlates with the phosphorylation of Cx43 serine residues. Further exploration of these effects identified a rapid transactivation of the Epidermal Growth Factor Receptor in a Toll-Like Receptor 4-dependent manner, preceding its internalization. In turn, cytosolic Ca2+ oscillations are generated. Both GJIC blockade and Ca2+ mobilization partially depend on ATP release through Cx43 and pannexin (Panx-1) channels, as demonstrated by blocking activity or expression of channels, and inactivating extracellular ATP. By monitoring dye-spreading into adjacent cells, we show that HSP70 released from human monocytes in response to macrophage colony-stimulating factor, prevents the formation of GJIC between monocytes and HMEC. Therapeutic manipulation of this pathway could be of interest in inflammatory and tumor growth.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Tapsigargina, ≥98% (HPLC), solid film
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Gja1
Sigma-Aldrich
MISSION® esiRNA, targeting human GJA1
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Npm1
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Gja3